[Sir]{.smallcaps}, We thank Al Arashi *et al.* \[[@rky037-B1]\] for their interest and comments on our recent report on tumour necrosis factor inhibitor (TNFi) survival and predictors of response in axial spondyloarthritis---findings from a United Kingdom cohort \[[@rky037-B2]\].

We did not focus specifically on sex differences in our analysis but have now undertaken further analyses on sex differences in our study population. We found a higher prevalence of acute anterior uveitis (44.9 *vs* 33.9%, *P* = 0.03) and family history of SpA (45.2 *vs* 30.4%, *P* = 0.02) in females, but not for IBD (females 16.8% *vs* males 11.9%, *P* = 0.19) or psoriasis (females 24.3% *vs* males 19.5%, *P* = 0.29). This is similar to previous studies, which reported that women are more affected by uveitis in SpA \[[@rky037-B3]\] and AS \[[@rky037-B4]\].

In our cohort, BASDAI50 response 3--6 months after initiation of index TNFi was achieved by 56 (58.3%) females and 219 (61.5%) males (*P* = 0.64). Discontinuation rates for index TNFi were higher in females (females *n* = 56, 37.3%; males *n* = 168, 33.5%). In addition, females had higher rates of adverse events (44.6 *vs* 33.9%), and males had a slightly higher proportion of primary non-response (15.5 *vs* 14.3%) and secondary non-response (20.8 *vs* 16.1%). None of these differences reached statistical significance.

In conclusion, there are differences between our cohort and those reported by Al Arashi *et al*. \[[@rky037-B1]\]; however, sample sizes are small. Larger prospective studies are required to evaluate sex differences in axSpA.
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